Therapeutic Asset Ratings
204 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
cd70-targeting car-t cells
Lung Cancer
Chongqing Precision Biotech Co., Ltd
P1
C
(37)
Cid-078 Monotherapy
Lung Cancer
Circle Pharma
P1
C
(37)
Clsp-1025
Lung Cancer
Clasp Therapeutics, Inc.
P1
C
(37)
Cpg-Odn
Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
P1
C
(37)
do-2
Lung Cancer
DeuterOncology
P1
C
(37)
Dp Cd8 Til
Lung Cancer
AgonOx, Inc.
P1
C
(37)
gc203 til
Lung Cancer
Shanghai Juncell Therapeutics
P1
C
(37)
Guadecitabine
Lung Cancer
Memorial Sloan Kettering Cancer Center
P1
C
(37)
Hbi-2438
Lung Cancer
HUYABIO International, LLC.
P1
C
(37)
hs-10504
Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
hs-20117
Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
hs-20122
Lung Cancer
Hansoh BioMedical R&D Company
P1
C
(37)
HUMAN FAECAL MATTER
Lung Cancer
M.D. Anderson Cancer Center
P1
C
(37)
Idov-Immune
Lung Cancer
ViroMissile, Inc.
P1
C
(37)
Kk-Lc-1 Tcr-T Cells
Lung Cancer
Christian Hinrichs
P1
C
(37)
Loperamide
Lung Cancer
M.D. Anderson Cancer Center
P1
C
(37)
Lutetium [177Lu] Bl-Arc001
Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(37)
MNPR-101-DFO-89Zr
Lung Cancer
Monopar Therapeutics
P1
C
(37)
Mnpr-101-Pcta-177Lu
Lung Cancer
Monopar Therapeutics
P1
C
(37)
QXL138AM
Lung Cancer
Nammi Therapeutics Inc
P1
C
(37)
RSC-1255
Lung Cancer
RasCal Therapeutics, Inc.
P1
C
(37)
Sarilumab
Lung Cancer
M.D. Anderson Cancer Center
P1
C
(37)
Shr-1826
Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
Shr-A2009
Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
Shr-A2102
Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
Showing 151 to 175 of 204 assets
Previous
Page 7 of 9
Next